AIM ImmunoTech Inc. (AIM) — Analysis Summary
AIM ImmunoTech Inc. (AIM) has a market cap of $7.18M with year-over-year revenue growth of -48.2%. Net margin stands at -15861.4%. The stock trades at a P/E ratio of -0.5.
Key Takeaways
- Revenue changed -48.2% year-over-year
- Net margin of -15861.4%
- P/E ratio of -0.5
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, AIM posted revenue growth of -48.2% and trades at a P/E of -0.5.
AIM ImmunoTech Inc. (AIM)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -9.5x — earnings do not cover interest payments
Operating margin at -11724.2% — severe operating losses
Net margin at -15021.1% — losses exceed revenue (possible one-time charges)
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
21
Headquarters
OCALA, FL
Exchange
XASE
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.